文献速递血栓与止血

血小板RNA测序用于无诱因静脉血栓栓塞症患者癌症筛查:一项前瞻性队列研究

Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study.
PubMed 文献 · J Thromb Haemost · 2023-01-11

在13个中心招募≥40岁无诱因静脉血栓栓塞症患者,随访12个月观察癌症发生,比较血小板RNA测序与标准有限癌症筛查的诊断准确性。共纳入476例,随访期间25例(5.3%)诊断为癌症。血小板RNA测序的受试者工作特征曲线下面积为0.54(95%CI 0.41-0.66),在当前算法下对隐匿性癌症的诊断准确性差。

要点

  • 无诱因静脉血栓栓塞症患者12个月随访癌症检出率为5.3%(25/476)。
  • 标准有限癌症筛查灵敏度72%(95%CI 52-86),特异度91%(95%CI 82-95)。
  • 血小板RNA测序ROC曲线下面积0.54(95%CI 0.41-0.66),诊断准确性差。

核心结论

  • 在当前算法下,血小板RNA测序对无诱因静脉血栓栓塞症患者隐匿性癌症的诊断准确性差。

研究设计与样本

  • 前瞻性队列研究,在13个中心招募≥40岁无诱因静脉血栓栓塞症患者,随访12个月观察癌症发生。
  • 共纳入476例参与者,随访期间25例(5.3%)诊断为癌症;每例癌症患者随机选取3例无癌症患者进行分析。
  • 参与者接受标准有限癌症筛查,血小板RNA测序分析在研究结束时集中进行。

主要发现

  • 标准有限癌症筛查灵敏度72%(95%CI 52-86),特异度91%(95%CI 82-95)。
  • 血小板RNA测序的受试者工作特征曲线下面积为0.54(95%CI 0.41-0.66)。
  • 在预设主要阳性阈值0.54下,所有患者检测均为阳性,灵敏度估计为100%(95%CI 87-99),特异度为8%(95%CI 3.7-16.4)。
  • 在预设次要阈值0.89下,灵敏度为68%(95%CI 48-83;与有限筛查比较P=0.71),特异度为36%(95%CI 26-47)。

关键数值与推荐

  • 血小板RNA测序预设主要阳性阈值0.54,目标检测灵敏度86%。
  • 血小板RNA测序预设次要阈值0.89,目标检测特异度99%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platelet RNA sequencing has been shown to accurately detect cancer in previous studies. OBJECTIVES: To compare the diagnostic accuracy of platelet RNA sequencing with standard-of-care limited cancer screening in patients with unprovoked venous thromboembolism (VTE). METHODS: Patients aged ≥40 years with unprovoked VTE were recruited at 13 centers and followed for 12 months for cancer. Participants underwent standard-of-care limited cancer screening, and platelet RNA sequencing analysis was performed centrally at study end for cases and selected controls. Sensitivity and specificity were calculated, using the predefined primary positivity threshold of 0.54 for platelet RNA sequencing aiming at 86% test sensitivity, and an additional predefined threshold of 0.89 aiming at 99% test specificity. RESULTS: A total of 476 participants were enrolled, of whom 25 (5.3%) were diagnosed with cancer during 12-month follow-up. For each cancer patient, 3 cancer-free patients were randomly selected for the analysis. The sensitivity of limited screening was 72% (95% CI, 52-86) at a specificity of 91% (95% CI, 82-95). The area under the receiver operator characteristic for platelet RNA sequencing was 0.54 (95% CI, 0.41-0.66). At the primary positivity threshold, all patients had a positive test, for a sensitivity estimated at 100% (95% CI, 87-99) and a specificity of 8% (95% CI, 3.7-16.4). At the secondary threshold, sensitivity was 68% (95% CI, 48-83; p value compared with limited screening 0.71) at a specificity of 36% (95% CI, 26-47). CONCLUSION: Platelet RNA sequencing had poor diagnostic accuracy for detecting occult cancer in patients with unprovoked VTE with the current algorithm.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Mulder FI, Kraaijpoel N, Carrier M, et al. Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study. J Thromb Haemost. 2023. PMID: 36841648. doi:10.1016/j.jtha.2023.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。